| Literature DB >> 32612373 |
Shuang Yang1, Qian Liu1, Zhen Shen1, Hua Wang1, Lei He1.
Abstract
PURPOSE: Catheter-related infection (CRI) is one of the most frequent causes of hospitalizations for immunocompromised patients. A major challenge is the increased prevalence of Myroides odoratimimus. The purpose of the present study was to evaluate the clinical features and molecular characteristics of M. odoratimimus collected from a general hospital in Shanghai, China. PATIENTS AND METHODS: From July 2015 to August 2016, a total of 22 isolates of M. odoratimimus were collected from inpatients respectively from the biliary and pancreatic surgery (6/22) and the urology department (16/22). Clonal relatedness among the isolates was assessed using pulsed-field gel electrophoresis (PFGE) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). Moreover, the antimicrobial susceptibility tests were carried out using the Clinical and Laboratory Standards Institute (CLSI) broth microdilution method. The presence of antibiotic resistance genes was screened using the polymerase chain reaction (PCR) assay. Additionally, protein structure prediction was analyzed using PSIPRED and RaptorX.Entities:
Keywords: Flavobacterium; MUS-1; Myroides odoratimimus; nosocomial; outbreak
Year: 2020 PMID: 32612373 PMCID: PMC7323792 DOI: 10.2147/IDR.S251626
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Primers for the Carbapenemase Gene Sequencing Analysis
| Gene Name | Primer Name | Sequence |
|---|---|---|
| 5ʹ-AGGACTTTGGCGGCTCCAT-3’ | ||
| 5ʹ-TCCCTCGAGCGCGAGTCTA-3’ | ||
| 5ʹ-GCGTGGTTAAGGATGAACAC-3’ | ||
| 5ʹ-CATCAAGTTCAACCCAACCG-3’ | ||
| 5ʹ-GATGGTGTTTGGTCGCATA-3’ | ||
| 5ʹ-CGAATGCGCAGCACCAG-3’ | ||
| 5ʹ-GGAATAGAGTGGCTTAAYTCTC-3’ | ||
| 5ʹ-GGTTTAAYAAAACAACCACC-3’ | ||
| 5ʹ-CGTTAGGCACACCAGAAGAA-3’ | ||
| 5ʹ-ATGCGAGTCTTACCACACCT-3’ | ||
| 5ʹ-TTAATCGTTTTTAGTTGA-3’ | ||
| 5ʹ-TTATAATTGCTTGTTGTT-3’ | ||
| 5ʹ-ATGGAATTGCCCAATATTATGC −3’ | ||
| 5ʹ-TCAGCGCAGCTTGTCGGC −3’ | ||
| B-F | 5ʹ-TAAATATGCCGCTAATGC-3’ | |
| B-R | 5ʹ-CCCCAGGTCTTTTGAATC-3’ |
Demographic Data of Patients Included in This Study
| Patient No. | Gender/Age | Diagnosis | Sample | Collection Date | Ward (Floor) | Infection Symptoms | Antibiotic Treatment After Operation | Outcome | PFGE | MALDI-TOF MS | MUS |
|---|---|---|---|---|---|---|---|---|---|---|---|
| RJ1 | F/60 | Pancreas neuroendocrine tumor | Drainage | 7-Sep-15 | Biliary and Pancreatic Surgery(13F) | None | Yes | Discharged with drainage tube | E | II | MUS-1 |
| RJ2 | M/76 | Hepatolithiasis | Drainage | 1-Sep-15 | Biliary and Pancreatic Surgery(13F) | None | Yes | Discharged with drainage tube | E | III | MUS-1 |
| RJ3 | M/43 | Pancreatic duct stones, choledochus cyst | Drainage | 18-Sep-15 | Biliary and Pancreatic Surgery(13F) | None | Yes | Discharged with drainage tube | E | III | MUS-1 |
| RJ4 | F/62 | Uremia,Hemodialysis | Drainage | 7-Sep-15 | Urology(16F) | None | Yes | Favourable | A | I | MUS-3 |
| RJ5 | M/47 | Pancreatic head carcinoma | Drainage | 25-Aug-15 | Biliary and Pancreatic Surgery(13F) | None | Yes | Favourable | E | II | MUS-1 |
| RJ6 | F/62 | Uremia | Drainage | 1-Aug-15 | Urology(16F) | None | Yes | Favourable | D | I | MUS-3 |
| RJ7 | M/41 | Uremia | Drainage | 5-Aug-15 | Urology(16F) | None | Yes | Favourable | C | III | MUS-3 |
| RJ8 | M/40 | Uremia | Drainage | 4-Aug-15 | Urology(16F) | None | Yes | Favourable | C | I | MUS-3 |
| RJ9 | M/62 | Uremia | Drainage | 23-Jul-15 | Urology(16F) | None | Yes | Favourable | C | I | MUS-3 |
| RJ10 | M/51 | Uremia | Drainage | 17-Jul-15 | Urology(16F) | None | Yes | Favourable | C | I | MUS-3 |
| RJ11 | M/56 | Common bile duct stones, liver cancer | Drainage | 7-Sep-15 | Biliary and Pancreatic Surgery(13F) | Fever | Yes | Died | E | II | MUS-1 |
| RJ12 | M/41 | Uremia | Drainage | 12-Jan-16 | Urology(16F) | None | Yes | Favourable | A | I | MUS-3 |
| RJ13 | M/57 | Renal carcinoma | Drainage | 24-Jan-16 | Urology(16F) | Fever | Yes | Favourable | A | I | MUS-3 |
| RJ14 | M/52 | Chronic pancreatitis and pancreatic duct stone | Bile | 26-Jan-15 | Biliary and Pancreatic Surgery(13F) | Fever | Yes | Favourable | F | III | MUS-1 |
| RJ15 | M/28 | Uremia | Drainage | 21-May-16 | Urology(16F) | None | Yes | Favourable | A | I | MUS-3 |
| RJ16 | F/53 | Uremia | Drainage | 1-Jun-16 | Urology(16F) | None | Yes | Favourable | A | I | MUS-3 |
| RJ17 | M/31 | Uremia | Drainage | 1-Jun-16 | Urology(16F) | None | Yes | Favourable | A | I | MUS-3 |
| RJ18 | M/57 | Uremia | Drainage | 4-Jun-16 | Urology(16F) | None | Yes | Favourable | A | I | MUS-3 |
| RJ19 | F/38 | Uremia | Drainage | 4-Jun-16 | Urology(16F) | None | Yes | Favourable | A | I | MUS-3 |
| RJ20 | M/36 | Uremia | Drainage | 4-Jun-16 | Urology(16F) | None | Yes | Favourable | A | I | MUS-3 |
| RJ21 | F/36 | Uremia | Urine | 22-Jul-16 | Urology(16F) | Fever | Yes | Favourable | B | IV | MUS-3 |
| RJ22 | F/46 | Ureteral occlusion | Drainage | 8-Aug-16 | Urology(16F) | None | Yes | Discharged with drainage tube | B | IV | MUS-3 |
Figure 1PFGE image of the M. odoratimimus strains. The 22 isolates belonged to six distant PFGE groups (types A–F) by using a cut-off of 80% similarity (Δurology department, □biliary and pancreatic surgery department).
Figure 2MALDI-TOF MS dendrograms for 22 isolates. Using PCA cluster analysis to construct a dendrogram, MALDI-TOF MS generated four clusters (types I, II, III, and IV) with a cut-off value of 3.
Summary of MIC Results Among the 22 M. odoratimimus Isolates
| Isolate No. | MIC(mg/mL) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TZP | CAZ | CRO | FEP | ATM | CIP | AK | CN | IPM | MEM | LEV | SXT | |
| RJ1 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | >256 | >256 | 4 | 4 |
| RJ2 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | >256 | >256 | 4 | 4 |
| RJ3 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | >256 | >256 | 4 | 4 |
| RJ4 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | 8 | 8 | >256 | 8 |
| RJ5 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | >256 | >256 | 4 | 8 |
| RJ6 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | 8 | 8 | >256 | >256 |
| RJ7 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | >256 | >256 | 4 | 8 |
| RJ8 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | 16 | 4 | >256 | 32 |
| RJ9 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | 8 | 4 | >256 | 16 |
| RJ10 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | 8 | 4 | >256 | 16 |
| RJ11 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | >256 | 64 | 8 | 2 |
| RJ12 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | >256 | >256 | >256 | 16 |
| RJ13 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | >256 | >256 | 8 | 256 |
| RJ14 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | >256 | 128 | >256 | 4 |
| RJ15 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | 32 | 8 | 16 | 256 |
| RJ16 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | 32 | 8 | >256 | 128 |
| RJ17 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | 32 | 8 | >256 | 128 |
| RJ18 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | 64 | 8 | >256 | 256 |
| RJ19 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | 32 | 8 | >256 | 128 |
| RJ20 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | 8 | 8 | >256 | 256 |
| RJ21 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | 16 | 16 | >256 | 128 |
| RJ22 | ≥128 | ≥64 | ≥64 | ≥64 | ≥64 | ≥4 | ≥64 | ≥16 | 8 | 4 | >256 | 64 |
Notes: MIC breakpoints, imipenem (S≤4, I=8, R≥16); meropenem (S≤4, I =8, R≥16); levofloxacin (S≤2, I=4, R≥8); trimethoprim–sulfamethoxazole(S ≤2, R≥4).
Abbreviations: MIC, minimum inhibitory concentration; R, resistant; I, intermediate; S, sensitive; TZP, piperacillin–tazobactam; CAZ, ceftazidime; CRO, ceftriaxone; FEP, cefepime; ATM, aztreonam; CIP, ciprofloxacin; AK, amikacin; CN, gentamicin; IPM, imipenem; MEM, meropenem; SXT, trimethoprim–sulfamethoxazole; LEV, levofloxacin.
Figure 3The level of resistance to meropenem between the clinical isolates of MUS-1 from the biliary and pancreatic surgery ward and MUS-3 from the urology ward (P < 0.05).
Figure 4The secondary and tertiary structure prediction of MUS-1 wild-type and V60A-mutant proteins using bioinformatics tools. (A) Secondary structure prediction of the MUS wild-type protein by PSIPRED. (B) Secondary structure prediction of the MUS-3 (V60A) mutant protein by PSIPRED. A beta-strand is predicted to form at the mutation position (red triangle). (C) Tertiary structure prediction of the MUS protein by RaptorX, with the mutation marked inside (black oval).